AR Holding

AR Holding Company, Inc. is a pharmaceutical holding entity primarily known for its ownership and management of intellectual property related to Colcrys (colchicine), a treatment for gout and familial Mediterranean fever. The company emerged as a key player in the colchicine market following the FDA's Unapproved Drugs Initiative, which led to the first formal approval of the drug under the brand name Colcrys. AR Holding has been involved in significant patent litigation to protect its market exclusivity and has historically operated in close association with AR Scientific and Mutual Pharmaceutical Company. While Takeda Pharmaceuticals acquired the commercial rights to Colcrys, AR Holding continues to hold relevant patents and legal interests in the product's lifecycle.